Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583677 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1LMNAGAAKMT2A | |
| SCHEMBL20583456 | 0.76 | KMT2A (0.53) | KDM4EALDH1A1LMNAGAAKMT2A | |
| SCHEMBL18641821 | 0.76 | KDM4E (0.37) | KDM4EALDH1A1LMNAGAAKMT2A | |
| SCHEMBL7354510 | 0.73 | KDM4E (0.50) | KDM4EALDH1A1LMNAGAAKMT2A | |
| SCHEMBL7345401 | 0.73 | — | — | |
| SCHEMBL20583620 | 0.71 | KDM4E (0.33) | KDM4EALDH1A1LMNAGAARAB9A | |
| SCHEMBL7351663 | 0.71 | KDM4E (0.53) | KDM4EALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL2305382 | 0.69 | KDM4E (0.35) | KDM4E | |
| SCHEMBL2305380 | 0.69 | KDM4E (0.35) | KDM4E | |
| SCHEMBL3489240 | 0.68 | ALDH1A1 (0.38) | KDM4EALDH1A1LMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20210093611-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3782994-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10918622-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3390395-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200276162-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2020-09-03 | — | — | US | disclosed |
| US-10695323-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10464905-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10342780-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190135762-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20180362512-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2018-12-20 | — | — | US | disclosed |
| EP-3390395-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103611-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | REDX PHARMA PLC (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062239-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-20180362512-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-20190135762-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-10918622-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-20200276162-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-10695323-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-20210093611-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-10464905-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-10342780-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885ALDH1A1 4454/4885LMNA 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.